Top Markets
#1 Purr Purr +59.03%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Pons Pons +35.37%
#4 Kinetiq Kinetiq +28.28%
#5 ApeX ApeX +24.56%
#6 Non-Playable Coin Non-Playable Coin +20.51%
#7 Morpho Morpho +19.21%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.77%
#9 OriginTrail OriginTrail +18.36%
#10 Pudgy Penguins Pudgy Penguins +18.08%
Coin of the day
Purr Purr
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Coya Therapeutics, Inc. Coya Therapeutics, Inc.

Coya Therapeutics, Inc.

COYA
Classifica tra le azioni #21166
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on... Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Prezzo delle azioni
$4.83
Ultima sincronizzazione: 2026-08-21
Capitalizzazione di mercato
$113.30M
Variazione (1 giorno)
-0.62%
Variazione (1 anno)
-29.59%
Paese
US
Scambia Coya Therapeutics, Inc. (COYA)

Categoria

Healthcare
Il prezzo COYA con la capitalizzazione del mercato della B
Coya Therapeutics, Inc. Coya Therapeutics, Inc.
COYA
$4.83
Capitalizzazione di mercato di Coya Therapeutics, Inc.(COYA)
Capitalizzazione di mercato: $113.30M
A partire dal August 2026, Coya Therapeutics, Inc. ha una capitalizzazione di mercato pari a $113.30M. Questo rende Coya Therapeutics, Inc. la 21166th azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di Coya Therapeutics, Inc. dal 2022 al 2026
COYA in paragone con la classifica dei più popolari stocks
Il prezzo per COYA Attivo B Capitalizzazione del mercato a B Risultati
Coya Therapeutics, Inc. Coya Therapeutics, Inc.
$222,166 $113.30M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.211T +4,599,611.65%
Coya Therapeutics, Inc. Coya Therapeutics, Inc.
$193,833 $113.30M
Apple Inc. Apple Inc.
AAPL
$4.547T +4,012,995.40%
Coya Therapeutics, Inc. Coya Therapeutics, Inc.
$177,451 $113.30M
Alphabet Inc. Alphabet Inc.
GOOG
$4.162T +3,673,827.06%
Coya Therapeutics, Inc. Coya Therapeutics, Inc.
$153,164 $113.30M
Microsoft Corporation Microsoft Corporation
MSFT
$3.593T +3,171,005.65%
Coya Therapeutics, Inc. Coya Therapeutics, Inc.
$119,062 $113.30M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.793T +2,464,957.61%